Core Insights - GE HealthCare Technologies raised its annual adjusted profit forecast due to strong demand for its medical devices in the United States [1] - The company beat estimates for third-quarter results, indicating robust performance in the healthcare sector [1] Financial Performance - The third-quarter results exceeded market expectations, showcasing the effectiveness of GE HealthCare's product offerings [1] - The increase in annual adjusted profit forecast reflects confidence in continued growth and demand for medical devices [1] Market Demand - Strong demand for medical devices in the United States has been a significant driver of the company's performance [1] - The healthcare industry is experiencing a positive trend, benefiting companies like GE HealthCare that focus on innovative medical solutions [1]

Core Viewpoint - GE HealthCare Technologies reported a decline in profit for the third quarter, primarily due to increased costs associated with tariffs [1] Financial Performance - The company's profit fell in the third quarter, indicating a negative impact on financial performance [1] Cost Factors - The added costs of tariffs were highlighted as a significant factor contributing to the profit decline [1]

Revenue Performance - Total revenues for Q3 2025 were $5,143 million, representing a 6% increase year-over-year, with organic growth of 4%[183] - For the nine months ended September 30, 2025, total revenues reached $14,927 million, a 4% increase year-over-year, with organic growth of 3%[184] - The U.S. and Canada region generated $2,358 million in Q3 2025, a 5% increase from the previous year[182] - The EMEA region saw a 10% revenue increase to $1,360 million in Q3 2025[182] - Total revenues for the three months ended September 30, 2025, were $5,143 million, a 6% increase compared to $4,863 million in the same period of 2024[204] Segment Performance - Product sales increased by 5% or $174 million, driven by strong growth in Pharmaceutical Diagnostics (PDx), Imaging, and Advanced Visualization Solutions (AVS)[183] - Service sales grew by 6% or $107 million, primarily due to growth in new and existing customer contractual agreements[183] - Segment revenues for Imaging were $2,349 million in Q3 2025, a 5% increase from Q3 2024[181] - PDx segment revenues increased by 20% to $749 million in Q3 2025, with a 10% organic growth[181] - Imaging segment revenues were $2,349 million, growing 5% or $120 million, driven by growth in the EMEA and USCAN regions[185] - AVS segment revenues were $1,301 million, growing 7% or $84 million, with strength in the U.S. market[185] - PDx segment revenues were $749 million, growing 20% or $124 million, driven by the acquisition of Nihon Medi-Physics Co., Ltd. and an increase in Organic revenue, which grew 10%[185] Income and Profitability - The company reported a net income attributable to GE HealthCare of $446 million for Q3 2025, compared to $470 million in Q3 2024[180] - Operating income for Q3 2025 was $653 million, a decrease from $676 million in Q3 2024[180] - Net income attributable to GE HealthCare for the nine months ended September 30, 2025, was $1,495 million, an increase of 18% compared to the previous year[186] - Adjusted EBIT for the three months ended September 30, 2025, was $761 million, a decrease of 4% compared to the previous year[188] - Gross profit decreased by $36 million or 300 basis points as a percent of Total revenues due to increased costs of products and services sold[190] Expenses and Taxation - Total operating expenses decreased by $13 million, with a decrease in R&D investments of $25 million[190] - Provision for income taxes increased by $11 million primarily due to U.S. and foreign tax law changes[190] - Adjusted tax expense for the nine months ended September 30, 2025, was $(377) million, a decrease from $(401) million in 2024, with an adjusted effective tax rate of 20.2% compared to 21.9% in 2024[214] Cash Flow and Capital Structure - Free cash flow for the nine months ended September 30, 2025, was $589 million, down 21% from $743 million in 2024, with cash from operating activities decreasing by 10% to $937 million[217][226] - Cash and cash equivalents as of September 30, 2025, totaled $4,027 million, with access to revolving credit facilities of $3,500 million[218] - Total debt increased to $10,282 million as of September 30, 2025, from $8,951 million at the end of 2024, primarily due to new senior unsecured notes issued[229] - Cash generated from financing activities for the nine months ended September 30, 2025, was $910 million, including $1,487 million from new senior unsecured notes issuance[224] - Operating activities generated cash of $937 million for the nine months ended September 30, 2025, with net income of $1,552 million[220] Capital Expenditures and Compliance - Capital expenditures for the nine months ended September 30, 2025, were $348 million, primarily for manufacturing capacity expansion and new product introductions[227] - The company maintained compliance with credit facility covenants as of September 30, 2025, including the maximum consolidated net leverage ratio[230] - Credit ratings as of October 22, 2025, were Baa2 from Moody's, BBB from S&P, and BBB from Fitch, all with a stable outlook[233]

Financial Performance - Revenue for Q3 2025 was $5.1 billion, representing a 6% increase year-over-year, with organic revenue growth of 4% driven by EMEA and the U.S.[7] - Net income attributable to GE HealthCare was $446 million, down from $470 million in the prior year, resulting in a net income margin of 8.7%[7] - Diluted earnings per share (EPS) were $0.98, a decrease of $0.05 from the previous year, while adjusted EPS was $1.07, down $0.06 year-over-year[7] - Adjusted net income for Q3 2025 was $490 million, a decrease of 6% from $521 million in Q3 2024; for the nine months ended September 30, 2025, it increased by 3% to $1,441 million from $1,393 million in 2024[33] - The company reported a 18% increase in net income attributable to GE HealthCare for the nine months ended September 30, 2025, reaching $1,495 million compared to $1,272 million in 2024[33] Cash Flow and Investments - Cash flow from operating activities was $593 million, a decrease of $149 million year-over-year, and free cash flow was $483 million, down $168 million year-over-year[7] - Cash from operating activities for continuing operations decreased to $937 million in 2025 from $1,042 million in 2024, reflecting a decline of 10%[18] - Cash flows from investing activities for continuing operations totaled $(778) million in 2025, compared to $(674) million in 2024, indicating increased investment activity[18] - The company issued new debt amounting to $1,494 million in 2025, up from $994 million in 2024, reflecting a strategy to enhance liquidity[18] - Cash, cash equivalents, and restricted cash at the end of the period increased to $4,030 million in 2025 from $3,572 million in 2024[18] Revenue Segments - Imaging segment revenues were $2.349 billion, with a year-over-year growth of 5%, while Pharmaceutical Diagnostics saw a 20% increase in revenues[8] - Organic orders growth was 6%, with growth across all segments, and total company book-to-bill ratio was 1.06 times[6] - Total revenues for the nine months ended September 30, 2025, reached $14,927 million, a 4% increase from $14,353 million in 2024[26] - Organic revenue for the nine months ended September 30, 2025, was $14,792 million, representing a 3% growth compared to $14,349 million in 2024[26] - The company reported a 20% increase in PDx revenues for the three months ended September 30, 2025, reaching $749 million compared to $625 million in 2024[26] Guidance and Future Outlook - The company raised the lower end of its full-year 2025 adjusted EPS guidance range, now expecting adjusted EPS between $4.51 and $4.63[10] - Tariff impacts are estimated to affect adjusted EBIT by approximately $265 million and adjusted EPS by $0.45 for the full year[12] Operational Highlights - The company launched several new products, including CareIntellect for Perinatal and the AI-supported solution for radiation therapy workflow[11] - GE HealthCare announced the intent to acquire icometrix to enhance its neurology portfolio with brain MRI assessment solutions[11] - Non-operating benefit costs for Q3 2025 were $(75) million, compared to $(102) million in Q3 2024[33] - Restructuring costs for Q3 2025 were $31 million, up from $22 million in Q3 2024; for the nine months ended September 30, 2025, restructuring costs totaled $71 million, down from $90 million in 2024[33] Company Recognition and Contact Information - GE HealthCare is recognized as one of the 2025 Fortune World's Most Admired Companies™[49] - Investor Relations contact is Carolynne Borders, reachable at +1-631-662-4317[49] - Media contact is Jennifer Fox, reachable at +1-414-530-3027[49] - The company encourages following its social media channels for the latest news[49] - More information can be found on the official website: https://www.gehealthcare.com[49] Tax and Effective Rates - The effective tax rate for Q3 2025 was 27.8%, compared to 25.5% in Q3 2024; the adjusted effective tax rate was 21.8% for Q3 2025, up from 18.7% in Q3 2024[37]

Oct 29, 2025 6:20 AM Eastern Daylight Time GE HealthCare reports third quarter 2025 financial results Share CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2025. GE HealthCare President and CEO Peter Arduini said, "We delivered robust orders with growth across all segments in the third quarter. This was led by customer demand for our differentiated solutions and a healthy capital equipment environment. Revenue performance was ...

Core Insights - The convergence of consumer technology, ambulatory monitoring, and traditional medical systems is reshaping cardiac care, with intellectual property control being a key determinant for leadership in diagnostics [1][4] - Cardiovascular disease is the leading cause of death globally, with a significant market opportunity of $133 billion for portable, connected diagnostic systems [2][4] Company Analysis - Major players in consumer wearables such as Apple, Samsung, Google/Fitbit, and others have introduced heart rate tracking and single-lead ECGs, but these technologies are limited to rhythm screening and do not achieve the diagnostic accuracy of 12-lead ECGs [7] - Companies like HeartBeam, iRhythm, and AliveCor are advancing portable systems that aim for diagnostic-grade performance, with HeartBeam being the first to offer a cable-free 12-lead ECG [7] Intellectual Property Landscape - PatentVest's analysis identified 581 patent families across 243 organizations, highlighting a competitive landscape where traditional device manufacturers like Philips and GE Healthcare face challenges from emerging innovators such as HeartBeam and AliveCor [7]

Core Viewpoint - GE HealthCare Technologies Inc. (GEHC) is expected to report third-quarter 2025 results on October 29, with anticipated steady top-line growth driven by its Advanced Visualization Solutions and Pharmaceutical Diagnostics segments, despite facing tariff pressures [1][2]. Financial Performance - In the last reported quarter, GEHC's adjusted earnings per share (EPS) was $1.06, exceeding the Zacks Consensus Estimate by 16.48%, with an average surprise of 12.53% over the last four quarters [1]. - For the upcoming third quarter, GEHC's revenues are estimated at $5.07 billion, reflecting a 4.2% year-over-year increase, while EPS is projected to be $1.05, indicating a 7.9% decrease from the prior year [7][10]. Segment Analysis - **Imaging**: The Imaging segment showed 1% organic revenue growth in the second quarter, supported by demand in the U.S. and EMEA, but faced challenges in China. Tariffs impacted EBIT margin by 110 basis points, although strong backlog and capital demand are expected to sustain growth [4]. - **Advanced Visualization Solutions (AVS)**: AVS achieved 2% organic growth in the second quarter, driven by AI-enhanced ultrasound platforms. Upcoming product launches are anticipated to support continued momentum in the third quarter [5]. - **Patient Care Solutions (PCS)**: PCS revenues were flat in the second quarter, with margin pressures due to inflation. Third-quarter results may reflect ongoing margin weakness, with improvements expected only after a product refresh cycle completes in 2026 [6]. - **Pharmaceutical Diagnostics (PDx)**: PDx grew 5% organically in the second quarter, supported by increased imaging volumes and strong demand for specific tracers. This segment is expected to help offset weaknesses in PCS [7]. Margin and Cost Outlook - Tariffs are projected to be the primary headwind for earnings, with management guiding for a high-single-digit EBITDA decline in the third quarter. The gross margin decreased by 180 basis points in the second quarter, with half attributed to trade costs [9]. - Despite these pressures, robust backlog conversion and pricing discipline may partially cushion the impact of tariffs on margins [9]. Long-Term Growth Strategy - GEHC's long-term growth is supported by a strong innovation pipeline, including next-generation imaging solutions and AI integration in ultrasound platforms. The company aims for mid-single-digit organic growth over the next several years while expanding margins [18][20]. - The company has a record backlog of $21 billion and is focused on strategic collaborations and sustained R&D investment to enhance its market position [20].

Core Insights - General Electric (GE) has a long history of innovation and has recently experienced a resurgence in its stock performance after a significant decline during the Great Recession [1][3][4] Company Overview - GE was founded in 1892 by Thomas Edison and has been a pioneer in various fields including hydroelectric power, aviation, and healthcare [2] - The company underwent a major restructuring in 2021, splitting into three publicly traded entities: GE Aerospace, GE Vernova, and GE HealthCare Technologies [4] Performance Analysis - GE Aerospace has shown the strongest performance among the three entities, with a stock increase of 727% over the past five years, while GE Vernova increased by 417% and GE HealthCare only by about 20% [5] - GE Aerospace reported a market capitalization of approximately $321 billion and revenue exceeding $35 billion last year, with expectations to rise by 16% to nearly $41 billion this year [6] Recent Financial Results - In the third quarter, GE Aerospace reported adjusted revenue growth of 26% to $11.3 billion and earnings growth of 44% to $1.66 per share, surpassing Wall Street expectations [8] - New orders increased by 5% to $10.3 billion, with defense revenue experiencing a significant jump of 26% [8]

Core Insights - GE HealthCare Technologies Inc. (GEHC) has received the CE mark for its Carevance patient monitor, which is expected to enhance accessible and reliable care for customers in Europe [1][11] - Carevance expands GE HealthCare's modular monitoring solutions portfolio, aiming to provide a unified monitoring solution adaptable to various patient needs [2][6] - The regulatory clearance is anticipated to significantly bolster GE HealthCare's Monitoring Solutions business and strengthen its market position [3][9] Company Performance - Following the announcement of the CE mark, GE HealthCare's shares increased by nearly 0.8% [4] - The company currently has a market capitalization of $34.74 billion and an earnings yield of 5.9%, outperforming the industry's negative yield [5] - In the last reported quarter, GE HealthCare achieved an earnings surprise of 16.5% [5] Product Significance - Carevance is designed to provide clinically reliable and cost-effective monitoring solutions, addressing challenges such as staffing shortages and increasing patient complexity [6][11] - The new Cardiac Output Insights feature in Carevance allows for advanced hemodynamic monitoring without the need for additional hardware or invasive procedures [7] Industry Prospects - The global cardiac output monitoring device market is projected to grow from $3.11 billion in 2024 to $5 billion by 2035, with a CAGR of approximately 4.4% [8] - Factors driving this growth include the adoption of advanced monitoring technologies and the acceptance of less invasive procedures [8] Recent Developments - GE HealthCare has announced collaborations with The Queen's Health Systems and Duke Health to advance AI-driven hospital operations software [10] - The company also launched CareIntellect for Perinatal and unveiled the Carestation 850 anesthesia delivery system [12]

Core Viewpoint - GE HealthCare has received CE mark for its Carevance patient monitor, enhancing accessible and reliable care for customers in Europe [1] Group 1: Product Details - Carevance is built on GE HealthCare's clinical excellence, providing a clinically reliable and cost-effective solution [1] - The monitor features validated parameters and an intuitive, efficient workflow to support care teams in focusing on patients [1] Group 2: Market Context - Hospitals are currently facing new challenges, which the Carevance monitor aims to address [1]